ENT-03 is under clinical development by Enterin and currently in Phase I for Type 2 Diabetes. According to GlobalData, Phase I drugs for Type 2 Diabetes have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ENT-03’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ENT-03 overview
ENT-03 is under development for the treatment of Alzheimer's disease, type 2 diabetes and obesity. It is administered by subcutaneous route.
It was also under development for multiple sclerosis.
Enterin overview
Enterin operate as pharmaceutical and healthcare company developing novel compounds to treat parkinson’s disease. The company’s products pipeline include ENT-01 and ENT-03. Its novel drug candidate repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Enterin products are used for the treatment of parkinson’s disease, autism spectrum disorder, alzheimer’s disease, schizophrenia, huntington’s disease. The company has operations in Tampa Bay, Sarasota, Boca Raton, Port Charlotte, Georgetown, Los Angeles, New York, Philadelphia, Cleveland, Detroit, Michigan, and Denver in the US. Enterin is headquartered in Philadelphia, Pennsylvania the US.
For a complete picture of ENT-03’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
